Reshma A. Rangwala
Merck & Co., Inc., Rahway, NJ, USA (United States)
2 papers in the Anchorcite directory, published between 2015 and 2016, cited 16,570 times in total.
Research topics
- Cancer Immunotherapy and Biomarkers · 2 papers
- Lung Cancer Treatments and Mutations · 2 papers
- Lung Cancer Diagnosis and Treatment · 1 paper
- Lung Cancer Research Studies · 1 paper
Frequent co-authors
- Rina Hui · 2 papers
- Gregory M. Lubiniecki · 2 papers
- Martin Reck · 1 paper
- Delvys Rodríguez‐Abreu · 1 paper
- Andrew George Robinson · 1 paper
- Tibor Csőszi · 1 paper
- Andrea Fülöp · 1 paper
- Maya Gottfried · 1 paper
Papers
- Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung CancerNew England Journal of Medicine · 2016 · 10,276 citations
BACKGROUND: Pembrolizumab is a humanized monoclonal antibody against programmed death 1 (PD-1) that has antitumor activity in advanced non-small-cell lung cancer (NSCLC), with increased activity in tumors that express programmed death ligand 1 (PD-L1). METHODS: In this open-label, phase 3…
- Pembrolizumab for the Treatment of Non–Small-Cell Lung CancerNew England Journal of Medicine · 2015 · 6,294 citations
BACKGROUND: We assessed the efficacy and safety of programmed cell death 1 (PD-1) inhibition with pembrolizumab in patients with advanced non-small-cell lung cancer enrolled in a phase 1 study. We also sought to define and validate an expression level of…
Metadata from OpenAlex (CC0).